Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant and wildtype .
作者信息
Deng Andrew L, Kim Yu Ri, Lichtenstein Emily A, O'Connor Owen A, Deng Changchun
机构信息
Columbia University Medical Center, Center for Lymphoid Malignancies, New York, NY, USA.
Department of Internal Medicine, Yonsei University, Seoul, Korea.
出版信息
Haematologica. 2017 Jul;102(7):e275-e277. doi: 10.3324/haematol.2016.161893. Epub 2017 Mar 24.
Abstract
摘要
相似文献
1
Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant and wildtype .
Haematologica. 2017 Jul;102(7):e275-e277. doi: 10.3324/haematol.2016.161893. Epub 2017 Mar 24.
2
MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
Cancer. 2017 Apr 1;123(7):1166-1173. doi: 10.1002/cncr.30404. Epub 2016 Dec 4.
3
Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations.
Blood Cancer J. 2014 Dec 12;4(12):e266. doi: 10.1038/bcj.2014.87.
4
High prevalence of and mutations in intravascular large B-cell lymphoma.
Blood. 2018 May 3;131(18):2086-2089. doi: 10.1182/blood-2017-12-822817. Epub 2018 Mar 7.
5
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
Nat Med. 2015 Aug;21(8):922-6. doi: 10.1038/nm.3884. Epub 2015 Jul 20.
6
High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma.
Leukemia. 2014 Mar;28(3):719-20. doi: 10.1038/leu.2013.348. Epub 2013 Nov 20.
7
Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations.
JCI Insight. 2017 Mar 23;2(6):e90196. doi: 10.1172/jci.insight.90196.
8
Mutational frequencies of CD79B and MYD88 vary greatly between primary testicular DLBCL and gastrointestinal DLBCL.
Leuk Lymphoma. 2018 May;59(5):1260-1263. doi: 10.1080/10428194.2017.1370546. Epub 2017 Sep 3.
9
[Combination of zanubrutinib and rituximab in the treatment of primary cutaneous diffuse large B-cell lymphoma leg type with CD79B and MYD88 mutations: a case report].
Zhonghua Xue Ye Xue Za Zhi. 2023 Mar 14;44(3):258. doi: 10.3760/cma.j.issn.0253-2727.2023.03.015.
10
Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
Oncotarget. 2015 Dec 8;6(39):42232-42. doi: 10.18632/oncotarget.6273.
引用本文的文献
1
Unveiling Primary Cutaneous B-Cell Lymphomas: New Insights into Diagnosis and Treatment Strategies.
Cancers (Basel). 2025 Apr 1;17(7):1202. doi: 10.3390/cancers17071202.
2
Genetic Stability of Driver Alterations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type and Their Relapses: A Rationale for the Use of Molecular-Based Methods for More Effective Disease Monitoring.
Cancers (Basel). 2022 Oct 20;14(20):5152. doi: 10.3390/cancers14205152.
3
Cytologic and Molecular Diagnostics for Vitreoretinal Lymphoma: Current Approaches and Emerging Single-Cell Analyses.
Front Mol Biosci. 2021 Jan 11;7:611017. doi: 10.3389/fmolb.2020.611017. eCollection 2020.
4
Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice.
Cancers (Basel). 2020 Oct 10;12(10):2913. doi: 10.3390/cancers12102913.
5
Large B - Cell Lymphoma of the Leg - Unfavourable Course with Rituximab/Bendamustin.
Open Access Maced J Med Sci. 2019 Jun 30;7(18):3006-3008. doi: 10.3889/oamjms.2019.565. eCollection 2019 Sep 30.
6
Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy.
Int J Mol Sci. 2018 Jun 13;19(6):1758. doi: 10.3390/ijms19061758.
本文引用的文献
1
Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: A retrospective case series.
Neurology. 2017 Jan 3;88(1):101-102. doi: 10.1212/WNL.0000000000003420. Epub 2016 Nov 18.
2
MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia.
N Engl J Med. 2015 Aug 6;373(6):584-6. doi: 10.1056/NEJMc1506192.
3
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
Nat Med. 2015 Aug;21(8):922-6. doi: 10.1038/nm.3884. Epub 2015 Jul 20.
4
High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites.
Blood Cancer J. 2013 Sep 6;3(9):e139. doi: 10.1038/bcj.2013.28.
5
Nuclear factor-κB pathway-activating gene aberrancies in primary cutaneous large B-cell lymphoma, leg type.
J Invest Dermatol. 2014 Jan;134(1):290-292. doi: 10.1038/jid.2013.265. Epub 2013 Jun 13.
6
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.
Blood. 2013 Aug 15;122(7):1222-32. doi: 10.1182/blood-2012-12-475111. Epub 2013 Jul 8.
7
MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
N Engl J Med. 2012 Aug 30;367(9):826-33. doi: 10.1056/NEJMoa1200710.
8
Oncogenically active MYD88 mutations in human lymphoma.
Nature. 2011 Feb 3;470(7332):115-9. doi: 10.1038/nature09671. Epub 2010 Dec 22.
Zotero 插件